Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 19/20 | 1.00 |
| ▸ | CASP7 | P55210 | 15/20 | 1.00 |
| ▸ | CASP1 | P29466 | 7/20 | 1.00 |
| ▸ | CASP6 | P55212 | 4/20 | 1.00 |
| ▸ | CASP9 | P55211 | 4/20 | 1.00 |
| ▸ | CASP2 | P42575 | 4/20 | 1.00 |
| ▸ | CASP4 | P49662 | 2/20 | 1.00 |
| ▸ | CASP8 | Q14790 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263591 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL7736082 | 0.98 | CASP3 (0.96) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL4156166 | 0.94 | CASP3 (1.00) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL4143950 | 0.94 | CASP3 (1.00) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL6535137 | 0.91 | CASP3 (0.84) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL6535139 | 0.91 | CASP3 (0.84) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL6535718 | 0.90 | CASP3 (0.82) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL2259069 | 0.90 | CASP3 (0.82) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL6535499 | 0.90 | CASP3 (0.82) | CASP3CASP7CASP1CASP6CASP9 | |
| SCHEMBL6535497 | 0.90 | CASP3 (0.82) | CASP3CASP7CASP1CASP6CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | claimed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | claimed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | claimed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | claimed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8329686-B2 | Isatin analogues and uses therefor | WASHINGTON UNIVERSITY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | WASHINGTON UNIVERSITY IN ST. LOUIS | 2009-03-12 | — | — | US | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1087663-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999065451-A2 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | CASP3 4/4885CASP7 37/4885CASP1 29/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | CASP3 5/4885CASP7 28/4885CASP1 18/4885 |
| US-20090068105-A1 | ISATIN ANALOGUES AND USES THEREFOR | CASP7, CASP3, HASPIN | CASP3 2/4885CASP7 1/4885CASP1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.